509 related articles for article (PubMed ID: 21983214)
1. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children.
Black S; Nicolay U; Vesikari T; Knuf M; Del Giudice G; Della Cioppa G; Tsai T; Clemens R; Rappuoli R
Pediatr Infect Dis J; 2011 Dec; 30(12):1081-5. PubMed ID: 21983214
[TBL] [Abstract][Full Text] [Related]
2. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
3. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
4. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v).
Skowronski DM; Janjua NZ; De Serres G; Purych D; Gilca V; Scheifele DW; Dionne M; Sabaiduc S; Gardy JL; Li G; Bastien N; Petric M; Boivin G; Li Y
J Infect Dis; 2012 Dec; 206(12):1852-61. PubMed ID: 22872731
[TBL] [Abstract][Full Text] [Related]
5. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N
Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
[TBL] [Abstract][Full Text] [Related]
9. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
Plennevaux E; Blatter M; Cornish MJ; Go K; Kirby D; Wali M; Reeves-Hoché MK; Denis M
Vaccine; 2011 Feb; 29(8):1569-75. PubMed ID: 21219979
[TBL] [Abstract][Full Text] [Related]
10. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
[TBL] [Abstract][Full Text] [Related]
11. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I
Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791
[TBL] [Abstract][Full Text] [Related]
12. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection.
Ohmit SE; Petrie JG; Cross RT; Johnson E; Monto AS
J Infect Dis; 2011 Dec; 204(12):1879-85. PubMed ID: 21998477
[TBL] [Abstract][Full Text] [Related]
13. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM
Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967
[TBL] [Abstract][Full Text] [Related]
14. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
[TBL] [Abstract][Full Text] [Related]
15. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
Zuccotti G; Amendola A; Viganò A; Pariani E; Zappa A; Pogliani L; Giacomet V; Savarino A; Podestà A; Rottoli A; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2007 Sep; 25(37-38):6692-8. PubMed ID: 17697730
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
Ruiz-Palacios GM; Leroux-Roels G; Beran J; Devaster JM; Esen M; Launay O; McElhaney JE; van Essen GA; Benoit A; Claeys C; Dewé W; Durand C; Duval X; Falsey AR; Feldman G; Galtier F; Gervais P; Hwang SJ; McNeil S; Richardus JH; Trofa A; Oostvogels L;
Hum Vaccin Immunother; 2016 Dec; 12(12):3043-3055. PubMed ID: 27690762
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
[TBL] [Abstract][Full Text] [Related]
19. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
[TBL] [Abstract][Full Text] [Related]
20. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.
Skowronski DM; De Serres G; Dickinson J; Petric M; Mak A; Fonseca K; Kwindt TL; Chan T; Bastien N; Charest H; Li Y
J Infect Dis; 2009 Jan; 199(2):168-79. PubMed ID: 19086914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
